News

The decision to file the protocol was made after the FDA accepted without comment the report on the results of the traumatic brain injury (TBI) Phase II-a safety

Under the terms of the agreement, Raven will license its proprietary whole cell immunization technology for use with Bioprocessing Technology Institute (BTI)’s stem cells. Raven will screen the

Under this agreement, Sangamo will provide a non-exclusive, worldwide license to Open Monoclonal Technologies (OMT) for the commercial use of transgenic animals generated using Sangamo’s proprietary zinc finger

The offer represents an 18% premium over the closing price of LifeCell’s stock on April 4, 2008, and a 26% premium over the 90-day volume weighted average trading

The company expects that the net proceeds of the offering will be approximately $13.4 million after deducting underwriting discounts and other expenses associated with the offering. The company

The new center, which will be located in Camp Hill, is said to have been designed with patient comfort and efficiency in mind, and will have a total

The $30 million in funding will be provided by Deerfield from two sources: $20 million under a royalty and funding agreement and $10 million from the sale of

Paul Viviano, chairman of the board and CEO of Alliance Imaging, said: “This acquisition and the opportunity to develop a strategic relationship with Accuray provides Alliance’s national team

In the second quarter of 2008, the company intends to initiate the randomized, double-blind, placebo controlled Phase III program to evaluate the efficacy and safety of Ketotransdel in